KURA — Kura Oncology Share Price
0.000.00%
Last trade - 00:00- $1.34bn
- $920.82m
- 31
- 22
- 88
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.36 | ||
| Price to Tang. Book | 3.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.08% | ||
| Return on Equity | -37.34% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 14.07 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Directors
- Troy Wilson CHM (52)
- Kathleen Ford COO (74)
- Stephen Dale OTH (49)
- Kirsten Flowers OTH (46)
- Bridget Martell OTH (55)
- Teresa Bair SEC (50)
- Faheem Hasnain LED
- Helen Collins DRC (58)
- Carol Schafer DRC (57)
- Thomas Malley IND (52)
- Diane Parks IND (69)
- Steven Stein IND (54)
- Mary Szela IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 16th, 2007
- Public Since
- November 5th, 2015
- No. of Shareholders
- 106
- No. of Employees
- 142
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 76,180,620
- Address
- 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, 92130
- Web
- https://www.kuraoncology.com/
- Phone
- +1 8585008800
- Auditors
- Ernst & Young LLP
Upcoming Events for KURA
Kura Oncology Inc Annual Shareholders Meeting
Kura Oncology Inc Annual Shareholders Meeting
Q2 2024 Kura Oncology Inc Earnings Release
Similar to KURA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Kura Oncology share price?
As of Today at 19:13 UTC, shares in Kura Oncology are trading at $17.53. This share price information is delayed by 15 minutes.
How has the Kura Oncology share price performed this year?
Shares in Kura Oncology last closed at $17.53 and the price had moved by +62.77% over the past 365 days. In terms of relative price strength the Kura Oncology share price has outperformed the S&P500 Index by +35.45% over the past year.
What are the analyst and broker recommendations for Kura Oncology?
The overall consensus recommendation for Kura Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kura Oncology dividend yield?
Kura Oncology does not currently pay a dividend.
Does Kura Oncology pay a dividend?
Kura Oncology does not currently pay a dividend.
When does Kura Oncology next pay dividends?
Kura Oncology does not currently pay a dividend.
How do I buy Kura Oncology shares?
To buy shares in Kura Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kura Oncology?
As of the previous close price of $17.53, shares in Kura Oncology had a market capitalisation of $1.34bn.
Where are Kura Oncology shares listed?
Here are the trading details for Kura Oncology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KURA
What kind of share is Kura Oncology?
Based on an overall assessment of its quality, value and momentum Kura Oncology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kura Oncology share price forecast for 2024?
The analyst consensus target price for shares in Kura Oncology is $30.25. That is 72.56% above the last closing price of $17.53.
Analysts covering Kura Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$2.32 for the next financial year.
What is the trend in the Kura Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kura Oncology. Over the past six months, its share price has outperformed the S&P500 Index by +79.96%.
As of the last closing price of $17.53, shares in Kura Oncology were trading +28.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kura Oncology PE Ratio?
The Kura Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kura Oncology?
Kura Oncology's management team is headed by:
- Troy Wilson - CHM
- Kathleen Ford - COO
- Stephen Dale - OTH
- Kirsten Flowers - OTH
- Bridget Martell - OTH
- Teresa Bair - SEC
- Faheem Hasnain - LED
- Helen Collins - DRC
- Carol Schafer - DRC
- Thomas Malley - IND
- Diane Parks - IND
- Steven Stein - IND
- Mary Szela - IND